Epigenetic drug discovery: targeting DNA methyltransferases.

Abstract

Epigenetic modification of DNA leads to changes in gene expression. DNA methyltransferases (DNMTs) comprise a family of nuclear enzymes that catalyze the methylation of CpG dinucleotides, resulting in an epigenetic methylome distinguished between normal cells and those in disease states such as cancer. Disrupting gene expression patterns through promoter methylation has been implicated in many malignancies and supports DNMTs as attractive therapeutic targets. This review focuses on the rationale of targeting DNMTs in cancer, the historical approach to DNMT inhibition, and current marketed hypomethylating therapeutics azacytidine and decitabine. In addition, we address novel DNMT inhibitory agents emerging in development, including CP-4200 and SGI-110, analogs of azacytidine and decitabine, respectively; the oligonucleotides MG98 and miR29a; and a number of reversible inhibitors, some of which appear to be selective against particular DNMT isoforms. Finally, we discuss future opportunities and challenges for next-generation therapeutics.

DOI: 10.1177/1087057111421212

4 Figures and Tables

02040201220132014201520162017
Citations per Year

143 Citations

Semantic Scholar estimates that this publication has 143 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Foulks2012EpigeneticDD, title={Epigenetic drug discovery: targeting DNA methyltransferases.}, author={Jason M. Foulks and K. Mark Parnell and Rebecca N. Nix and Suzanna Chau and Krzysztof Swierczek and Michael Saunders and Kevin M Wright and Thomas F Hendrickson and Koc-Kan Ho and Michael V. McCullar and Steven B. Kanner}, journal={Journal of biomolecular screening}, year={2012}, volume={17 1}, pages={2-17} }